Hill Island Financial LLC Takes $341,000 Position in Eli Lilly and Company $LLY

Key Points

• Hill Island Financial LLC acquired a new position in Eli Lilly and Company, buying 437 shares valued at approximately $341,000 during the second quarter.
• Recent analyst reports show mixed sentiments, with target prices ranging from $715.00 to $1,050.00, indicating a cautious outlook for Eli Lilly's stock performance.
• Eli Lilly reported earnings of $6.31 per share, surpassing expectations and showing a 37.6% year-over-year revenue increase to $15.56 billion.

Hill Island Financial LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 437 shares of the company's stock, valued at approximately $341,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares during the period. Vest Financial LLC boosted its position in Eli Lilly and Company by 73.4% in the first quarter. Vest Financial LLC now owns 6,570 shares of the company's stock worth $5,426,000 after purchasing an additional 2,782 shares during the last quarter. Ehrlich Financial Group purchased a new position in Eli Lilly and Company in the first quarter worth $202,000. Finally, Pines Wealth Management LLC grew its stake in Eli Lilly and Company by 14.9% in the 1st quarter. Pines Wealth Management LLC now owns 4,079 shares of the company's stock valued at $3,369,000 after purchasing an additional 530 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent analyst reports. Leerink Partners reiterated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. JPMorgan Chase & Co. lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. Morgan Stanley dropped their target price on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research note on Friday. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $938.94.

Eli Lilly and Company Stock Up 2.5%

LLY opened at $840.46 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The company has a market cap of $795.47 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a 50 day moving average of $734.60 and a 200 day moving average of $765.98.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 EPS. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In related news, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 over the last quarter. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.